Phosphorylation of GPSM2 was shown to be significantly downregulated in untreated RA patients as compared to healthy controls and RA patients treated with IL-6 receptor inhibitors, making it a potential therapeutic target in the treatment of RA. The gene discussed is GPSM2; the disease is rheumatoid arthritis.